What this covers
This Business Breakdowns episode has Marc de Vos walk host Matt through Agilent, beginning with its lineage: Hewlett Packard's 1938 garage, an audio tester used by Disney on Fantasia, the 1965 purchase of F and M Scientific, and the 2014 Keysight spin-off that removed an electronic test business worth about 40% of sales. The company is then mapped by end market. Pharma is roughly a third of sales, chemicals and food and environmental testing about 20% each, and academia and government around 10%.
The middle of the conversation covers technical and commercial detail. Gas Chromatography versus Liquid Chromatography is explained by what the sample can survive, and Agilent holds about two-thirds of the gas market. Shares barely move, and a Waters sales chart shows a decades-flat line for one column type. Other threads include the PFAS testing market, said to be about $400 million and growing 20% a year, and Agilent's oligonucleotide unit, which began in 2006 and now supplies RNA-drug makers at volumes no rival matches. On service, the episode looks at density economics among technicians and at how separate instrument and service sales teams once let competitors win contracts. Pricing stays at low single digits.
The closing stretch turns to numbers and risk. Earnings have outgrown revenue, with operating margin near 34% in consumables and service against about 20% in life science instruments. EPS has compounded about 13% since 2015, and free cash flow is about $1.4 billion. The main cyclical exposure is pharma spending after the COVID buying surge, not NIH funding. Marc also reflects on the 2005 semiconductor sale that became Broadcom.
Agilent is an underappreciated, sticky lab-instrument business whose recurring consumables and service revenue, locked in by regulatory validation and incumbency, makes it a high-quality compounder that is easy to overlook as a 'boring' company.
- About two-thirds of revenue comes from consumables, service and software tied to the installed base, versus one-third from instrument sales
- Instruments are embedded in FDA-approved quality control processes, so switching is costly and risky for customers
- Pricing is low single digit and growth is mostly volume, with service density and attach-rate expansion driving margins
High switching costs deter customers because certified methods and bundled service make leaving rare.
- Switching providers is rare because methods are certified and service is bundled, so the cost of switching is a meaningful deterrent, which Matt identified as possibly the most meaningful point in the business.
“The point on the risk associated with switching providers might be the most meaningful thing.”